Molecular imaging in dementia

Article
First Online:
  • 113 Downloads

Keywords

Positron Emission Tomography Dementia Molecular Imaging Dementia With Lewy Body Molecular Imaging Modality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Chetelat G, Baron JC. Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging. Neuroimage 2003;18:525–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625–32.PubMedGoogle Scholar
  4. 4.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer’s disease using neuroimaging. Exp Gerontol. 2007;42:129–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Forstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging. 2004;25:1051–6.PubMedCrossRefGoogle Scholar
  10. 10.
    McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry. 2007;164:916–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Drzezga A, Riemenschneider M, Strassner B, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology. 2005;64:102–7.PubMedGoogle Scholar
  13. 13.
    Laws SM, Perneczky R, Drzezga A, et al. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. Am J Psychiatry. 2007;164:1577–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Reiman EM. Linking brain imaging and genomics in the study of Alzheimer’s disease and aging. Ann N Y Acad Sci. 2007;1097:94–113.PubMedCrossRefGoogle Scholar
  15. 15.
    Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102:8299–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Fellgiebel A, Dellani PR, Greverus D, Scheurich A, Stoeter P, Muller MJ. Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res. 2006;146:283–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Minati L, Grisoli M, Bruzzone MG. MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol. 2007;20:3–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Drzezga A, Grimmer T, Peller M, et al. Impaired cross-modal inhibition in Alzheimer disease. PLoS Med. 2005;2:e288.PubMedCrossRefGoogle Scholar
  19. 19.
    Prvulovic D, Van de Ven V, Sack AT, Maurer K, Linden DE. Functional activation imaging in aging and dementia. Psychiatry Res. 2005;140:97–113.PubMedGoogle Scholar
  20. 20.
    Sperling R. Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer’s disease. Ann N Y Acad Sci. 2007;1097:146–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 2006;21:89–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev. 1992;4:303–28.PubMedGoogle Scholar
  23. 23.
    Nordberg A. Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications. Biol Psychiatry. 2001;49:200–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Hasselbalch SG, Madsen K, Svarer C, et al. Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2007. in press. (Jun 1)Google Scholar
  25. 25.
    Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.PubMedGoogle Scholar
  27. 27.
    Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584–95.PubMedGoogle Scholar
  28. 28.
    Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRefGoogle Scholar
  29. 29.
    Games D, Buttini M, Kobayashi D, Schenk D, Seubert P. Mice as models: transgenic approaches and Alzheimer’s disease. J Alzheimers Dis. 2006;9:133–49.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Klinikum rechts der IsarTechnische UniversitätMunichGermany
  2. 2.Department of Psychiatry and Psychotherapy, Klinikum rechts der IsarTechnische UniversitätMunichGermany

Personalised recommendations